Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PREP | P48147 | 1/20 | 0.53 |
| ▸ | DPP4 | P27487 | 6/20 | 0.51 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.50 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.49 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.49 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.49 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | CACNA1G | O43497 | 3/20 | 0.47 |
| ▸ | CACNA1H | O95180 | 3/20 | 0.47 |
| ▸ | CACNA1I | Q9P0X4 | 3/20 | 0.47 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | FAP | Q12884 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11377543 | 0.80 | DPP4 (0.43) | PREPDPP4DPP8DPP7MEN1 | |
| SCHEMBL11380215 | 0.77 | DPP4 (0.50) | PREPDPP4DPP8DPP7FAP | |
| SCHEMBL6946115 | 0.77 | NPC1 (0.49) | DPP4DPP8DPP7CYP2C9CYP2C19 | |
| SCHEMBL11381209 | 0.75 | PREP (0.58) | PREPDPP4DPP8DPP7MEN1 | |
| SCHEMBL11373157 | 0.75 | PREP (0.49) | PREPDPP4DPP7 | |
| SCHEMBL11192909 | 0.73 | PREP (0.52) | PREPDPP4DPP8DPP7NPSR1 | |
| SCHEMBL3990079 | 0.73 | MEN1 (0.51) | HRH3ITGB1ITGA5NPSR1MEN1 | |
| SCHEMBL25471660 | 0.73 | PREP (0.43) | PREP | |
| SCHEMBL11375543 | 0.73 | PREP (0.53) | PREPDPP4DPP8DPP7FAP | |
| SCHEMBL6950171 | 0.73 | KMT2A (0.44) | DPP4DPP8MCL1KMT2ADPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1027041-B1 | NOVEL CYANOAZIRIDINES FOR TREATING CANCER | AMPLIMED INC (US) | 2003-10-22 | — | — | EP | disclosed |
| US-20030129222-A1 | Administering to a cancer patient a therapeutically effective amount of imexon or derivative in combination with one or more lipids to treat the cancer | VALLEY VENTURES III, L.P. | 2003-07-10 | — | — | US | disclosed |
| US-6297230-B1 | N-CARBAMOYL-SUBSTITUTED | AMPLIMED, INC. | 2001-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030129222-A1 | Administering to a cancer patient a therapeutically effective amount of imexon or derivative in combination with one or more lipids to treat the cancer | ABHD16A, PNLIP, LIPA | PREP 2593/4885DPP4 3112/4885DPP8 2904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.